Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financi...( WALTHAM Mass. March 27 /- Interle...),Health

WALTHAM, Mass., March 27 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) today announced results for the fourth quarter and year ended December 31, 2007.

The Company reported revenues of $9.7 million and a net loss of $6.2 million, or $(0.22) per basic and diluted common share, for the year ended December 31, 2007, and revenues of $2.3 million and a net loss of $1.5 million, or $(0.05) per basic and diluted common share, for the quarter ended December 31, 2007.

"I am pleased to be leading this exciting company and working to leverage its compelling science and unique market opportunities to help improve patient care. The Company's infrastructure, from its accredited CLIA lab to its distribution channel for nutritional supplements, Alan James Group, to its intellectual property, is unique to the industry," commented Lewis H. Bender, Chief Executive Officer. "While 2007 was a transitional year for Interleukin Genetics, from management's standpoint, we made several key advances within our pipeline and added outstanding scientific talent to our team. During the year, the Company conducted market research and initiated new research programs, and we have thus positioned ourselves well to address the increasingly important role of genetic testing in the field of personalized medicine."

Year End Results

Revenue for the year ended December 31, 2007 was $9.7 million compared to $4.7 million for the year ended December 31, 2006, an increase of $5.0 million or 105%. $4.8 million of the increase was due to the inclusion of the consumer products segment for all of 2007 compared to the 4 and 1/2 months post acquisition in 2006. Additionally, the Company's personal health segment increased revenues by $147,000
'/>"/>